Rahul Nayak

Rahul Nayak

Auto-generated profile, based on publicly available information

Rahul Nayak

Winship Cancer Institute, Emory University School of Medicine, Atlanta, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Current Opinion in Colloid & Interface Science
Verified
Journal Article
Closed access
GHGregory J. Hardy
Gregory J. Hardy
RNRahul Nayak
Rahul Nayak
SZStefan Zauscher
Stefan Zauscher

23 October 2019 in BMJ
Verified
Journal Article
Open access
PDF file
RNRahul K Nayak
Rahul K Nayak
JAJerry Avorn
Jerry Avorn
AKAaron S Kesselheim
Aaron S Kesselheim
Objective: To determine the extent to which late stage development of new drugs relies on support from public funding. Design: Cohort study. Setting: All new drugs containing one or more new molecular entities approved by the US Food and Drug Administration (FDA) between January 2008 and December 2017 via the new drug application pathway. Main outcome measures: Patents or drug development histories documenting late stage research contributions by a public sector research institution or a spin-off company, as well as each drug’s regulatory approval pathway and first-in-class designation. Results: Over the 10 year study period, the FDA approved 248 drugs containing one or more new molecular entities. Of these drugs, 48 (19%) had origins in publicly supported research and development and 14 (6%) originated in companies spun off from a publicly supported research program. Drugs in these groups were more likely to receive expedited FDA approval (68% v 47%, P=0.005) or be designated first in class (45% v 26%, P=0.007), indicating therapeutic importance. Conclusions: A review of the patents associated with new drugs approved over the past decade indicates that publicly supported research had a major role in the late stage development of at least one in four new drugs, either through direct funding of late stage research or through spin-off companies created from public sector research institutions. These findings could have implications for policy makers in determining fair prices and revenue flows for these products.

27 June 2012 in Journal of Materials Chemistry
Verified
Journal Article
Closed access
PDF file
GHGregory J. Hardy
Gregory J. Hardy
RNRahul Nayak
Rahul Nayak
SAS. Munir Alam
S. Munir Alam
JSJoe Shapter
Joe Shapter
FHFrank Heinrich
Frank Heinrich
SZStefan Zauscher
Stefan Zauscher
In this study, we present a technique to create complex, high cholesterol-containing supported lipid bilayers (SLBs) using α-helical (AH) peptide-induced vesicle fusion. Vesicles consisting of POPC : POPE : POPS : SM : Chol (9.35 : 19.25 : 8.25 : 18.15 : 45.00) were used to form a SLB that models the native composition of the human immunodeficiency virus-1 (HIV-1) lipid envelope. In the absence of AH peptides, these biomimetic vesicles fail to form a complete SLB. We verified and characterized AH peptide-induced vesicle fusion by a quartz crystal microbalance with dissipation monitoring, neutron reflectivity, and atomic force microscopy. Successful SLB formation entailed a characteristic frequency shift of −35.4 ± 0.8 Hz and a change in dissipation energy of 1.91 ± 0.23 × 10−6. Neutron reflectivity measurements determined the SLB thickness to be 49.9 +1.9 −1.5 Å, and showed the SLB to be 100 +0.0 −0.1% complete and void of residual AH peptide after washing. Atomic force microscopy imaging confirmed complete SLB formation and revealed three distinct domains with no visible defects. This vesicle fusion technique gives researchers access to a complex SLB composition with high cholesterol content and thus the ability to better recapitulate the native HIV-1 lipid membrane.

1 September 2015 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
RNRahul K. Nayak
Rahul K. Nayak
DWDavid Wendler
David Wendler
FMFranklin G. Miller
Franklin G. Miller
SKScott Y.H. Kim
Scott Y.H. Kim
Significant debate surrounds the issue of whether written consent is necessary for pragmatic randomized, controlled trials (RCTs) with low risk. To assess the U.S. public's views on alternatives to written consent for low-risk pragmatic RCTs. National experimental survey (2 × 2 factorial design) examining support for written consent versus general notification or verbal consent in 2 research scenarios. Web-based survey conducted in December 2014. 2130 U.S. adults sampled from a nationally representative, probability-based online panel (response rate, 64.0%). Respondent's recommendation to an ethics review board and personal preference as a potential participant on how to obtain consent or notification in the 2 research scenarios. Most respondents in each of the 4 groups (range, 60.3% to 71.5%) recommended written informed consent, and personal preferences were generally in accord with that advice. Most (78.9%) believed that the pragmatic RCTs did not pose additional risks, but 62.5% of these respondents would still recommend written consent. In contrast, a substantial minority in all groups (28.5% to 39.7%) recommended the alternative option (general notification or verbal consent) over written consent. Framing effects could have affected respondents' attitudes, and nonrespondents may have differed in levels of trust toward research or health care institutions. Most of the public favored written informed consent over the most widely advocated alternatives for low-risk pragmatic RCTs; however, a substantial minority favored general notification or verbal consent. Time-sharing Experiments for the Social Sciences and Intramural Research Program of the National Institutes of Health Clinical Center.

1 October 2014 in Health Affairs
Verified
Journal Article
Closed access
RNRahul K. Nayak
Rahul K. Nayak
SPSteven D. Pearson
Steven D. Pearson
In an effort to control health costs, payers are increasingly turning to step therapy (or "fail first") policies in pharmacy benefit design. These policies restrict coverage of expensive therapies unless patients have already failed treatment with a lower-cost alternative. More than other utilization management tools such as formulary tiering, step therapy raises important ethical concerns regarding the proper balance between cost control and the ability of patients and clinicians to tailor care to the needs of the individual patient. This article provides eight design criteria to guide the ethical development and evaluation of step therapy policies and describes six clinical scenarios in which step therapy may be appropriate. The ethical criteria and scenarios are intended to provide guidance and transparency for insurers, patients, clinicians, and policy makers in choosing and paying for the appropriate therapies.

4 October 2024 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SJShelley A. Jazowski
Shelley A. Jazowski
RNRahul K. Nayak
Rahul K. Nayak
SDStacie B. Dusetzina
Stacie B. Dusetzina